CSL Share Price
Latest Financial ReportsCSL Profile on ASX website
Computershare's Investor Centre website
Financial Calendar 2016
16 Feb -
Half Year Results
17 Aug -
Full Year Results
12 Oct -
Questions about my Shareholding
Please call CSL's share registry ComputerShare on 1800 646 882 for queries regarding address changes, dividend payments, etc.
About the CSL Group
CSL Limited News
CSL Behring News
Subscribe to News Alert
To receive the latest updates about CSL, sign up for our email
CSL Share Price
CSL Share Price page to access the quote table and price chart.
CSL is a global specialty biotherapeutics company that develops and delivers innovative biotherapies that save lives, and help people with life-threatening medical conditions live full lives.
With major facilities in Australia, Germany, Switzerland, United Kingdom and the U.S., CSL employs over 16,000 employees working in more than 30 countries.
FLUCELVAX QUADRIVALENT™ (Influenza Vaccine) - FDA Approval
CSL Limited (ASX:CSL; USOTC:CSLLY) - CSL today announced that the US Food and Drug Administration (FDA) has approved Seqirus’ FLUCELVAX QUADRIVALENT™ (Influenza Vaccine), the first four-strain, cell culture-derived, inactivated seasonal influenza vaccine for people aged four years and older. FLUCELVAX QUADRIVALENT helps protect against the two influenza A viruses and two B viruses recommended by the World Health Organization (WHO) and the FDA for the current influenza season.
IDELVION® (rFIX-FP) - European Commission Approval
CSL Limited (ASX:CSL; USOTC:CSLLY) today announced that, following the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) recommendation to grant marketing authorization for IDELVION® (Coagulation Factor IX (Recombinant), Albumin Fusion Protein) for patients with haemophilia B in late February 2016, the European Commission has now approved IDELVION for the treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency).
Seqirus Presentation to Investors/Analysts
Gordon Naylor, Russell Basser and Brent MacGregor deliver a presentation to investors and analysts during site tours at the Seqirus manufacturing facilities in Liverpool and Holly Springs.
IDELVION® (rFIX-FP) – FDA approval
CSL today announced that the U.S. Food and Drug Administration (FDA) has approved IDELVION [Coagulation Factor IX (Recombinant), Albumin Fusion Protein], CSL Behring’s novel, long-acting albumin fusion protein linking recombinant coagulation factor IX with recombinant albumin for the treatment of haemophilia B.
IDELVION® (rFIX-FP) - CHMP recommendation
CSL today announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorization for IDELVION®
(Coagulation Factor IX (Recombinant), Albumin Fusion Protein) for patients with haemophilia B.
CSL Appoints New Director
CSL Limited (ASX:CSL; USOTC:CSLLY) - CSL today announced that Dr Megan Clark AC has been appointed as a Director of the Company effective from 16 February 2016.
Half Year Result 2016 CSL Delivers Exceptional Performance
CSL Limited (ASX:CSL; USOTC:CSLLY) today announced a net profit after tax (NPAT) of US$719 million for the six months ended 31 December 2015, up US$27 million or 4% on a reported basis when compared to the prior comparable period (PCP). Earnings per share (EPS) grew 6%. After excluding financials relating to the recently acquired Novartis influenza vaccines business, underlying1
NPAT grew 7% and EPS grew 9%, at constant currency2
CSL Names David Lamont as Chief Financial Officer
CSL today named Mr. David Lamont, an accomplished global financial leader with a diverse commercial background, as its Chief Financial Officer (CFO), effective 2 January 2016. He will be based at CSL’s headquarters in Parkville, Australia. As announced in August, CSL CFO Mr. Gordon Naylor is transitioning to the role of President of Seqirus, the new global business created from the integration of bioCSL and the newly acquired Novartis influenza vaccines business.
Strong Full Year Result
CSL Limited (ASX:CSL; USOTC:CSLLY) today announced a net profit after tax (NPAT) of US$1,379 million for the full year ended 30 June 2015, up 6% on a reported basis when compared to the prior comparable period (PCP). NPAT grew 10% on a constant currency1
basis, after adjusting for the one-off costs2
associated with the acquisition of the Novartis influenza vaccine business.
Update on Novartis influenza vaccines acquisition
CSL Limited (ASX:CSL; USOTC: CSLLY) today announced that it has secured the necessary approvals required to proceed with the acquisition of the influenza vaccines business of Novartis and that it is working with Novartis to bring forward the close date for the transaction. The Company also said the new CSL subsidiary resulting from the acquisition will be called Seqirus.
Competitive Advanced Manufacturing - Quite within Reach for Australia
Securing a globally competitive locally-based advanced manufacturing sector is quite within reach for Australia, according to CSL Limited, Australia’s largest biotechnology company. The key is to make a serious, strategic effort to attract footloose global investment, especially targeting innovations and ideas developed in Australia.
CSL Behring to Present Pivotal Data for rVIII-SingleChain and rIX-FP at
CSL Limited (ASX:CSL; USOTC:CSLLY) today announced that CSL Behring will present more than 20 abstracts, including five oral presentations, from across its hematology portfolio of investigational and branded products at the 2015 International Society on Thrombosis and Haemostasis (ISTH) Congress being held in Toronto June 20 through 25. The presentations will include pivotal trial data for two of its late-stage recombinant products – its novel recombinant factor VIII SingleChain (rVIII-SingleChain) compound for hemophilia A and its long-acting recombinant factor IX albumin fusion protein (rIX-FP) for hemophilia B.
Gordon Naylor to lead CSL’s Global Influenza Vaccine Business
CSL Limited (ASX:CSL; USOTC:CSLLY) – CSL today announced that Gordon Naylor will lead CSL’s new global influenza vaccine business, which is planned for launch at the start of 2016. Mr Naylor is currently the Company’s Chief Financial Officer and has held executive management responsibility for CSL’s existing vaccines and pharmaceutical subsidiary, bioCSL, since 2012.
Half Year Result 2015
CSL Limited (ASX:CSL; USOTC:CSLLY) today announced a net profit after tax (NPAT) of US$692 million for the six months ended 31 December 2014, up US$47 million or 7% on a reported basis when compared to the prior comparable period (PCP). Earnings per share (EPS) grew 10%.
Prior ASX Releases
View the ASX Archive